Endometriosis Treatment Market Size to Surpass USD 5.74 Billion by 2034

The Market Is Poised for Robust Growth Through 2034

The global endometriosis treatment market is witnessing remarkable growth as awareness of this chronic gynecological disorder continues to rise worldwide. In 2024, the market was valued at USD 1.79 billion and is projected to increase to USD 2.01 billion in 2025. Over the next decade, it is expected to reach approximately USD 5.74 billion by 2034, growing at a strong CAGR of 12.35%. This upward trajectory is being driven by ongoing advancements in diagnostics, innovative drug formulations, and an increasing emphasis on women’s health in global healthcare agendas.

Endometriosis Treatment Market Key Points

• In terms of revenue, the global endometriosis treatment market was valued at USD 1.79 billion in 2024.
• It is projected to reach USD 5.74 billion by 2034.
• The market is expected to grow at a CAGR of 12.35% from 2025 to 2034.
• North America dominated the global endometriosis treatment market with the largest market share of 38% in 2024.
• Asia Pacific is expected to grow at a significant CAGR from 2025 to 2034.
• By drug type, the hormonal therapy segment contributed the biggest market share of 65% in 2024 and is expected to grow at the fastest rate over the forecast period.
• By surgery type, the conservative surgery segment held the major market share of 60% in 2024.
• By surgery type, the definitive surgery segment will grow at the highest CAGR between 2025 and 2034.
• By route of administration, the oral segment captured the largest market share of 55% in 2024.
• By route of administration, the injectables segment will expand at a significant CAGR between 2025 and 2034.
• By distribution channel, the hospital pharmacies segment held the highest market share of 45% in 2024.
• By distribution channel, the online pharmacies segment is expected to grow at the fastest CAGR between 2025 and 2034.
• By end-user, the hospitals and clinics segment accounted for biggest market share 50% in 2024.
• By end-user, the specialty centers segment is expected to expand at a significant compound annual growth rate (CAGR) between 2025 and 2034.

Hormonal Therapy Leads the Charge in Drug-Based Treatments

Among the various treatment types, hormonal therapy emerged as the leading drug segment, commanding 65% of the market share in 2024. These therapies—particularly GnRH agonists, oral contraceptives, and progestins—have been essential in managing endometriosis symptoms such as pain, inflammation, and heavy bleeding. Their widespread clinical use and effectiveness have positioned hormonal therapies as the cornerstone of treatment. Moreover, the development of next-generation hormonal drugs like GnRH antagonists is improving efficacy and reducing side effects, ensuring this segment continues to grow at a rapid pace.

Get a Sample: https://www.precedenceresearch.com/sample/6329

Conservative Surgery Remains the Preferred Option for Fertility Preservation

In terms of surgical treatment, conservative surgery dominated the market in 2024, accounting for 60% of the global revenue. This preference is driven by its ability to effectively remove endometrial lesions while preserving fertility—an essential factor for younger women. Procedures such as laparoscopy are increasingly common, especially in cases where medication fails to alleviate symptoms. Meanwhile, definitive surgeries like hysterectomy are projected to grow at the highest CAGR during the forecast period as they become more viable for patients with severe symptoms or treatment-resistant conditions.

Market Scope

Oral Medications Top the Charts for Patient Convenience

When evaluating route of administration, oral drugs held the largest market share (55%) in 2024. Their accessibility, affordability, and ease of use make them a preferred choice for patients and healthcare providers alike. Oral contraceptives and hormone pills are widely used to manage symptoms like chronic pelvic pain and irregular menstruation. However, injectable treatments are gaining momentum and are expected to expand at a significant CAGR due to their targeted delivery, long-acting effects, and ability to reduce the burden of daily medication.

Hospital Pharmacies Dominate, but Online Pharmacies Are Catching Up

Hospital pharmacies accounted for 45% of the market share in 2024, largely due to their access to specialized prescription drugs and their integration within treatment facilities. These pharmacies play a vital role in managing prescriptions following surgeries or hospital visits. Nevertheless, online pharmacies are emerging rapidly, driven by the convenience of home delivery, availability of virtual consultations, and accessibility in underserved regions. This segment is anticipated to grow at the fastest rate through 2034.

Hospitals and Clinics Offer Comprehensive, Multidisciplinary Care

In 2024, hospitals and clinics dominated the end-user landscape with a 50% market share. These institutions offer personalized, multidisciplinary care plans, making them the preferred choice for women seeking accurate diagnosis and holistic treatment. Their role in early-stage diagnosis and specialized surgical care is key to their dominance. However, specialty centers are expected to witness the fastest growth in the coming years. Their focused expertise, access to advanced diagnostic tools, and customized care plans make them increasingly attractive to patients.

North America Leads the Market, Thanks to Advanced Research and Infrastructure

North America held the largest share of the global market in 2024, accounting for 38% of revenue. The region’s dominance is attributed to the high prevalence of endometriosis, widespread awareness, and well-established healthcare infrastructure. In the U.S., the market size stood at USD 612.18 million in 2024 and is projected to grow to USD 1.99 billion by 2034, expanding at a CAGR of 12.57%. The region also benefits from substantial research funding and regulatory support. Notably, the NIH and Endometriosis Foundation of America are actively funding research into non-hormonal therapies, with recent projects launched at MSU and Oxford University.

Asia Pacific Emerges as the Fastest-Growing Region

Asia Pacific is poised for explosive growth, driven by population size, improving healthcare infrastructure, and rising awareness about women’s health. Countries like China and India are leading the charge. China benefits from robust government initiatives and increased pharmaceutical investment, especially in hormonal therapies. In India, the rise in multidisciplinary care centers and public health campaigns are significantly improving early diagnosis and access to care. The ASPIRE 2025 event in Singapore further solidified the region’s commitment to enhancing endometriosis treatment and fertility preservation through new clinical standards.

Europe Strengthens Its Position Through Innovation and Collaboration

Europe is another key region contributing to global market expansion. Germany, in particular, is seeing increased adoption of advanced diagnostics and minimally invasive surgeries. The region benefits from strong collaborations between public health systems and private pharmaceutical firms, enabling the fast development and adoption of targeted treatments. Major players such as Bayer, AbbVie, and AstraZeneca continue to introduce innovative oral medications and hormone modulators that are well-received in the European market.

Artificial Intelligence Is Revolutionizing Endometriosis Diagnosis and Treatment

AI is playing a transformative role in endometriosis care by improving diagnostic accuracy, optimizing treatment plans, and facilitating clinical research. Technologies that analyze medical imaging, genomics, and patient history are helping providers offer personalized treatments. Moreover, AI aids researchers in identifying biomarkers, accelerating drug discovery, and optimizing clinical trials. The integration of AI also enhances patient engagement through customized digital platforms that educate, monitor, and support individuals with endometriosis.

The Market Is Buzzing with Innovation and Partnerships

Recent developments are reshaping the landscape of endometriosis treatment. In March 2025, EDAP’s Focal One Robotics HIFU system received CE Mark certification for treating deep-infiltrating endometriosis. Around the same time, Heranova Lifesciences completed validation for HerResolve, a non-invasive diagnostic test designed to transform early detection and management. Meanwhile, Lisata Therapeutics is working with the University of Cincinnati to explore peptide-based therapies for endometriosis, showing how academia and industry are collaborating to deliver novel solutions.

Unmet Needs Still Exist, But So Do New Opportunities

While there is no definitive cure for endometriosis yet, growing investments in minimally invasive surgeries, non-hormonal therapies, and personalized medicine are helping to bridge the gap. A key restraint remains the need for long-term symptom management, which often frustrates patients. Yet this also presents an opportunity: stakeholders can meet this unmet need by developing cost-effective, patient-friendly solutions that offer lasting relief and improved quality of life.

Read Also: Chronotherapy Services Market Size to Attain USD 1,314.27 Million by 2034

Leading Players Are Investing in the Future of Women’s Health

Several major companies are deeply involved in shaping the future of endometriosis treatment, including:

• AbbVie Inc.

• Bayer AG

• Pfizer Inc.

• Merck & Co., Inc.

• Takeda Pharmaceutical

• AstraZeneca plc

• Myovant Sciences

• Teva Pharmaceuticals

• Mayne Pharma

• Ferring Pharmaceuticals

These players are not only launching new treatments but also forming strategic partnerships and investing in AI, diagnostics, and personalized care platforms.

Endometriosis Treatment Market Outlook: A Decade of Opportunity

As the endometriosis treatment market marches toward USD 5.74 billion by 2034, the focus will increasingly turn to personalized care, early diagnosis, AI integration, and global collaboration. While challenges remain, the growing emphasis on women’s health and innovation in both pharmaceutical and surgical domains ensure that the industry is well-positioned to meet the needs of millions of women globally